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Abstract
Background: Long-term growth hormone (GH) treatments in short children born small for gestational age (SGA)
restore lipid metabolism, but also increase insulin resistance. The aim of this study was to evaluate the influence of
long-term GH therapy on lipid and glucose metabolism as well as its dose dependency in short Japanese children
born SGA.
Methods: Eighty Japanese children with a short stature who were born SGA participated in this study; 65 were
treated with fixed GH doses of 0.033 (low) or 0.067 (high) mg/kg/day for 260 weeks; 15 were untreated controls in
the first year and were randomized to one of the two treatment groups at week 52. Serum cholesterol, glucose and
insulin levels were regularly measured. An oral glucose tolerance test (OGTT) was conducted annually.
Results: The mean age at the start of GH therapy was approximately 5.3 years. Serum total cholesterol (TC) and
low-density lipoprotein cholesterol (LDL-C) in the high dose group significantly decreased over time during GH
therapy. In both dose groups for TC, and in the high dose group for LDL-C, the higher the baseline values, the
greater the decrease after 260 weeks. The rate of the decrease observed after 260 weeks in patients with high
LDL-C levels was greater in the high dose group. Based on the results of OGTT, no patient was classified as being
diabetic; however, annual increases were observed in post-OGTT insulin levels. After 260 weeks, the homeostasis
model assessment as an index of insulin resistance (HOMA-IR) increased, suggesting that insulin resistance
developed over time with the GH treatment, while 36.6 % of the subjects entered puberty.
Conclusions: Long-term continuous GH treatment for children born SGA may have a potentially beneficial effect
on several parameters in lipid metabolism and does not adversely affect glucose metabolism.
Trial registration: GHLIQUID-1516, GHLIQUID-1517, Japan Pharmaceutical Information Center Clinical trial
registration: JapicCTI-050132. Registered 13 September 2005. Retrospectively registered. JapicCTI-050137.
Registered 13 September 2005. Retrospectively registered. ClinicalTrials.gov trial registration: NCT00184717.
Registered 13 September 2005. Retrospectively registered.
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Background
Small for gestational age (SGA) is defined as birth
weight and length below the 10th percentile for gesta-
tional age in Japan [1]. Approximately 10 % of children
born SGA will not achieve catch-up growth by 2 years
of age, and will remain short throughout their lives if left
untreated [2–4].
A previous study reported that low birth weight was
associated with the development of type 2 diabetes
mellitus, hypertension, and hyperlipidemia in adulthood
[5]. Furthermore, rapid catch-up in the weight of these
children has been suggested to increase the risk of vari-
ous medical conditions [6, 7].
The mechanisms underlying these risks have been
examined, with increases in insulin resistance and/or
intra-abdominal fat being implicated in this phenomenon
[8]. Increases in insulin resistance may cause impairments
in the growth hormone (GH)-insulin-like growth factor
(IGF)-binding protein axis or be a consequence of these
impairments [9].
GH treatments have been approved for the treatment
of children with short stature born SGA without spon-
taneous catch-up growth. GH therapy has been sug-
gested to provide additional, long-term metabolic
benefits, thereby mitigating the metabolic consequences
of being born SGA, while still facilitating early age-
appropriate catch-up growth [10]. On the other hand,
GH treatments have been reported to increase insulin
resistance with the over-secretion of insulin occurring to
compensate.
This was a 260 week (5 year) clinical study investigat-
ing the effect of long-term GH therapy in Japanese pa-
tients with SGA-related short stature. Height efficacy
and safety data [11] and the beneficial effects on meta-
bolic parameters (glucose, insulin, total cholesterol [TC],
low-density lipoprotein cholesterol [LDL-C], high-
density lipoprotein cholesterol [HDL-C]) [12] in these
patients have been reported previously. In the present
analysis, we examined the relationship between baseline
status and changes of lipid metabolism-associated pa-
rameters after long-term (260 weeks) GH therapy, in
addition to effects on other metabolic parameters in-
cluding glycated hemoglobin A1c (HbA1c), blood glucose
and insulin levels before and after an oral glucose toler-
ance test (OGTT), homeostasis model assessment as an




The study population comprised 80 short children
born SGA, aged 3–8 years, who were randomly
assigned to two groups receiving a low or high dose
(0.033 or 0.067 mg/kg/day) of GH (n = 31 and 34,
respectively). A control group (no treatment, n = 15)
was established during the first 52 weeks (1 year) and
compared with the GH therapy groups. Patients from
the control group were randomized to one of the
treatment groups at week 52. Further details concerning
inclusion and exclusion criteria have been described previ-
ously [11].
Study preparations
Packaging of trial products were indistinguishable
from one another and the doctors and the patients
were blinded to their group allocation. Both GH
doses were injected using a GH injection device (Nor-
diPen® 5 and PenNeedle®; Novo Nordisk A/S) to maintain
blinding.
Study design
This study involved a 156-week extension of a 104-
week (260 weeks in total) multicenter, randomized,
double-blind, parallel-group trial investigating the effi-
cacy and safety of two doses of GH. In patients
assigned to receive long-term GH therapy, GH was
subcutaneously injected daily before bedtime. In those
assigned to the control group (52 weeks), follow-up
alone was performed without GH. The trial was per-
formed between July 2003 and December 2009. Patient
visits were planned at 13-week intervals with a ±14-day
window, and 15 visits were scheduled over the course of
the 260-week trial.
Metabolic parameters assessed included: TC, LDL-C,
HDL-C, HbA1c, blood glucose and insulin levels before
and after an OGTT, HOMA-IR, and insulinogenic index
(Δinsulin 0–30 min/Δglucose 0–30 min).
On the basis of the results of OGTT (1.75 g/kg, max-
imum 75 g), individual patients were classified into three
types: normal, glucose intolerant, and diabetic, according
to the criteria for hyperglycemia established by the Japan
Diabetes Society [13, 14]. Patients were categorized as
glucose intolerant if they had a fasting blood glucose
level of 110–125 mg/dL and/or a value of 140–199 mg/dL
at 120 min after OGTT, or a blood glucose level of
180 mg/dL or more 60 min after OGTT. Changes in body
weight and body mass index (BMI) SDS were also
reported.
Statistical analysis
Summary statistics (mean with SD) were calculated for
baseline patient demographics. A closed testing procedure
was applied for analyses at 52 weeks since two hy-
potheses (low or high dose group vs. no treatment
group) were tested at 52 weeks. Changes from base-
line for the parameters of lipid metabolism were ana-
lyzed using a 2-sided t-test based on t-distribution for
each treatment group. A significance level of 5 % was
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used, and confidence intervals (CI) were constructed
with a confidence coefficient of 95 %. Simple correl-
ation analysis was used to evaluate the relationship
between baseline and change in the parameters of
lipid metabolism, between HOMA-IR and BMI SDS




Baseline patient demographics are outlined in Tables 1
and 2. No significant differences were observed in pa-
tient backgrounds at baseline among the three groups;
however, the proportion of boys was higher in the
low and high dose groups than in the no treatment
group. At treatment start, the mean age, height SDS, and
IGF-I SDS were approximately 5.3 years, –3.0, and –0.7,
respectively.
Influence on lipid metabolism
We analyzed lipid parameters at the start of GH therapy
and after 260 weeks. In the low dose group, no signifi-
cant differences were noted in the mean TC and LDL-C
levels between the two time points (Fig. 1a and b, re-
spectively). In the high dose group, a significant decrease
was observed after 260 weeks (p < 0.0005 and p < 0.0001,
respectively). In the low dose group, the mean HDL-
C level after 260 weeks was significantly higher than
at the start of GH therapy (p < 0.05, Fig. 1c), whereas
no significant difference was found in the high dose
group.
Correlations between the baseline values and changes
from baseline to 260 weeks in TC, LDL-C, and HDL-C
levels are shown in Fig. 2. Changes in TC levels were
negatively correlated with baseline values in the two
dose groups (Fig. 2a). A similar correlation was observed
between LDL-C levels at the start of GH therapy and the
change noted after 260 weeks (Fig. 2b). This correlation
was particularly strong in the high dose group. No cor-
relation was detected between HDL-C levels at the start
of GH therapy and the change noted after 260 weeks in
either group (Fig. 2c).
Influence on glucose metabolism
In the two dose groups, HbA1c (National Glycohemoglo-
bin Standardization Program [NGSP]) values increased
until 104 weeks after the start of GH therapy, and
remained constant thereafter (Fig. 3). In the low and
high dose groups, the mean HbA1c values at 260 weeks
after the start of GH therapy were 5.29 and 5.33 %,
respectively, which were within the normal range (4.6–
6.2 %). Furthermore, no patient showed an HbA1c value
beyond the standard value range during the study period
(260 weeks).
No marked changes were noted in the blood glu-
cose response to OGTT during 260 weeks of the
treatment in either group (Fig. 4). Regarding the in-
fluence of long-term GH therapy on insulin levels
after OGTT, the peak value in the high dose group
Table 1 Patient demographics [Mean ± SD]
No treatment 0.033 mg/kg/day 0.067 mg/kg/day
n n n
Gender 15 31 34
Male, % 46.7 7 64.5 20 58.8 20
Female, % 53.3 8 35.5 11 41.2 14
Chronological age, years 5.32 ± 1.38 15 5.34 ± 1.46 31 5.27 ± 1.15 34
Height, cm 94.6 ± 8.6 15 95.9 ± 8.4 31 94.9 ± 7.3 34
Height SDS -2.92 ± 0.53 15 -2.95 ± 0.64 31 -2.90 ± 0.67 34
BMI 14.07 ± 1.40 15 14.42 ± 1.26 31 14.16 ± 1.24 34
IGF-I, ng/mL 115.39 ± 51.01 15 117.25 ± 49.13 31 118.20 ± 49.10 34
IGF-I SDS -1.03 ± 1.50 15 -0.75 ± 1.06 31 -0.63 ± 1.21 34
Insulin, μU/mL 2.6 ± 1.7 10 3.6 ± 2.1 26 3.2 ± 1.9 28
Glucose, mg/dL 79.8 ± 6.3 15 82.4 ± 10.4 31 78.2 ± 11.5 34
HbA1c (NGSP), % 5.08 ± 0.32 15 5.10 ± 0.29 31 5.00 ± 0.19 34
TC, mg/dL 173.5 ± 24.2 15 166.9 ± 29.8 31 181.4 ± 24.2 34
LDL-C, mg/dL 96.7 ± 18.9 15 94.8 ± 26.2 31 104.7 ± 25.0 34
HDL-C, mg/dL 60.4 ± 15.9 15 56.9 ± 9.6 31 61.9 ± 12.0 34
SD standard deviation, SDS standard deviation score, BMI body mass index, IGF-I insulin-like growth factor-1, HbA1c glycated hemoglobin A1c, NGSP National
Glycohemoglobin Standardization Program, TC total cholesterol, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol
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was slightly higher than that in the low dose group
(Fig. 5).
Although no marked changes were observed in fasting
blood glucose levels, HbA1c values slightly increased
from 5.10 to 5.29 % and from 5.00 to 5.33 % in the low
and high dose groups, respectively. Two patients were
classified as being glucose intolerant based on fasting
blood glucose levels. GH therapy had not been adminis-
tered to one of these patients. In the low and high dose
groups, 95.7 and 85.2 % of patients were classified as be-
ing normal 260 weeks after the start of GH therapy, re-
spectively. No patients were classified as being diabetic
at any observation point.
An increase was noted in the mean HOMA-IR
260 weeks after the start of GH therapy (Table 3). How-
ever, no significant difference was noted in this increase
that was related to the dose administered. Twenty-two
patients (36.6 %) entered puberty during the study
period (7 [35 %] in the low dose group and 15 [37.5 %]
in the high dose group).
No correlations were found between the HOMA-
IR and BMI SDS or between the HbA1c and BMI
SDS after 260 weeks of GH therapy (data not
shown).
After 260 weeks of GH therapy, the insulinogenic
index increased from 0.45 to 1.31 and 0.52 to 1.24 in the
low and high dose groups, respectively; however, no
dose-related differences were observed.
Withdrawals
Two patients discontinued treatment and withdrew
from the study. One patient from the 0.033 mg/kg/
day group withdrew after 151 weeks due to IgA ne-
phropathy. The event was classed as a serious adverse
Fig. 1 (a) TC, (b) LDL-C, and (c) HDL-C values at baseline and week 260. TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C,
high-density lipoprotein cholesterol
Table 2 Patient numbers evaluated as being the glucose intolerant type of diabetes mellitus [n (%)]









Time point evaluated as the glucose
intolerant type
Before 60 mina 120 min Before 60 min* 120 min
Baseline 31 (100 %) 3 (9.7 %) 1 (3.2 %) 0 (0.0 %) 2 (6.5 %) 34 (100 %) 1 (2.9 %) 0 (0.0 %) 0 (0.0 %) 1 (2.9 %)
52 weeks 29 (100 %) 3 (10.3 %) 0 (0.0 %) 2 (6.9 %) 1 (3.4 %) 34 (100 %) 3 (8.8 %) 0 (0.0 %) 3 (8.8 %) 0 (0.0 %)
104 weeks 29 (100 %) 2 (6.9 %) 0 (0.0 %) 0 (0.0 %) 2 (6.9 %) 32 (100 %) 2 (6.3 %) 0 (0.0 %) 0 (0.0 %) 2 (6.3 %)
156 weeks 25 (100 %) 1 (4.0 %) 0 (0.0 %) 0 (0.0 %) 1 (4.0 %) 29 (100 %) 2 (6.9 %) 0 (0.0 %) 0 (0.0 %) 2 (6.9 %)
208 weeks 25 (100 %) 0 (0.0 %) 0 (0.0 %) 0 (0.0 %) 0 (0.0 %) 28 (100 %) 3 (10.7 %) 0 (0.0 %) 2 (7.1 %) 1 (3.6 %)
260 weeks 23 (100 %) 1 (4.3 %) 1 (4.3 %) 0 (0.0 %) 0 (0.0 %) 27 (100 %) 4 (14.8 %) 0 (0.0 %) 1 (3.7 %) 3 (11.1 %)
aPatients with a blood glucose level of 180 mg/dL or more 60 min after OGTT were regarded as being glucose intolerant [14]. OGTT, oral glucose tolerance test
Horikawa et al. International Journal of Pediatric Endocrinology  (2016) 2016:19 Page 4 of 9
event, moderate in severity and assessed as possibly
related to trial product. One patient from the no
treatment group/0.033 mg/kg/day withdrew after
212 weeks due to hyperinsulinemia. The event was
mild in severity and assessed as possibly related to trial
product.
Discussion
Influence on lipid metabolism
In the high dose group, significant decreases were found
in TC and LDL-C levels 260 weeks after the start of GH
therapy (Fig. 1). Mean TC decreased, especially in the
high dose group, and this change was attributed to a
decrease in LDL-C. The baseline status may have af-
fected these decreases, because baseline mean values
were significantly higher in male patients in the high
dose group, leading to more significant decreases with
the treatment, suggesting there might be a confound-
ing factor (data not shown). TC and LDL-C levels
were slightly lower in female patients. Since TC levels
normally increase with puberty [15], the degree of de-
crease in TC observed may have been attenuated by
pubertal hormonal changes. In the low dose group, a
significant increase was observed in HDL-C levels,
whereas no significant decreases were noted in TC
and LDL-C levels. However, the clinical significance
of this result currently remains unclear and awaits further
investigation.
After 260 weeks, decreases in TC in the two dose
groups and LDL-C in the high dose group correlated
Fig. 2 Scatter plots of (a) TC, (b) LDL-C, and (c) HDL-C values at baseline, and changes from baseline to week 260. TC, total cholesterol; LDL-C,
low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol
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with baseline values, indicating that the greater the
baseline value, the greater the decrease observed
after the treatment (Fig. 2). In both groups, a higher
TC was more likely to decrease during GH therapy.
This result is consistent with previous findings [16,
17], suggesting that long-term GH treatment has a
favorable lowering effect on cholesterol, especially in
those with higher cholesterol levels due to genetic
and/or environmental backgrounds. No correlation
was observed between HDL-C levels at the start of the
study and changes after 260 weeks of GH therapy. One
patient had markedly higher TC and LDL-C levels than
those of the other patients. This patient had a history of
IgA nephropathy, which may have elevated TC and LDL-
C levels [18].
Influence on glucose metabolism
Post-OGTT insulin levels increased with each year
of long-term GH treatment, particularly in the high
dose group (Fig. 5). It is possible that the increase in
HOMA-IR levels in the final year of GH therapy was
a result of patients transitioning into puberty. Over-
all, 35 % of patients in the low dose group and
37.5 % of patients in the high dose group entered
puberty during the study period. The increase in
post-OGTT insulin levels is consistent with previous
findings in which patients became relatively resistant
to insulin after the start of GH therapy [19]. Fasting
insulin levels have been shown to increase with age
[15]; therefore, the results obtained in this study
reflected physiological changes. Previous studies
demonstrated that bioactive IGF-I levels increased
through decreases in IGF-binding protein in the
presence of hyperinsulinemia [20]. Furthermore, an
increase in insulin levels has been suggested to pro-
mote growth [21].
After long-term GH therapy (260 weeks), the
HOMA-IR (Table 3) and insulinogenic index in-
creased. However, no significant differences were ob-
served between the two dose groups, indicating no
dose dependency. These results also demonstrated
that the GH dose of 0.033 mg/kg/day was already
greater relative to GH secreted from the pituitary in
normal physiology. Patients with a HOMA-IR of 2.5
or higher are regarded as being resistant to insulin
[13, 14], and 25 % of patients in this study (low dose
group: 5 out of 20 patients, high dose group: 4 out of
16 patients) exhibited insulin resistance after 260 weeks
of GH therapy. These results suggest that, although
the dose may be increased in accordance with the re-
sponsiveness of individual patients to GH therapy, dose
elevations within these limits do not influence glucose
tolerance.
No correlations were observed between the HOMA-IR
and BMI SDS or between the HbA1c and BMI SDS after
260 weeks of GH therapy. The mean BMI SDS in this
study was below 0 SD during the study period and our
patients did not include those with a very high/low BMI.
A larger number of patients need to be analyzed in future
studies in order to more clearly elucidate the relation-
ship between BMI and glucose metabolism in GH-treated
SGA.
Fig. 3 HbA1c (NGSP) during the study period. HbA1c, glycated hemoglobin A1c; NGSP, National Glycohemoglobin Standardization Program
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Conclusions
This study investigated the effect of long term con-
tinuous GH treatment in children born SGA on lipid
and glucose metabolism. In the high dose group, TC
and LDL-C levels decreased significantly over time
during the GH therapy. Baseline values correlated
with the reductions after 260 weeks in both groups
for TC and in the high dose group for LDL-C. This
result suggests that the long-term GH treatment used
had favorable lowering effects on cholesterol, espe-
cially in those with higher cholesterol levels. HbA1c
values slightly increased, and post-OGTT insulin
levels increased with each year of GH treatment;
however, no marked changes were noted in the blood
glucose response to OGTT during the 260 weeks of
treatment. In healthy adolescents, decreased insulin sensi-
tivity observed during puberty is compensated for by an
increase in insulin secretion, hence the increase in
HOMA-IR levels observed in the final year of GH therapy
may have been a result of patients transitioning into
puberty.
The results of this study suggest long-term continuous
GH treatment for children born SGA may have poten-
tially beneficial effects on several parameters of lipid me-
tabolism and does not have an adverse effect on glucose
metabolism.
Fig. 5 Changes in insulin after OGTT. a 0.033 mg/kg/day;
b 0.067 mg/kg/day. OGTT, oral glucose tolerance test





Baseline 0.720 ± 0.465 0.646 ± 0.498
260 weeks 2.154 ± 1.682 1.895 ± 1.197
SD standard deviation, HOMA-IR homeostatic model assessment as an index of
insulin resistance
Fig. 4 Changes in glucose after OGTT. a 0.033 mg/kg/day;
b 0.067 mg/kg/day. OGTT, oral glucose tolerance test
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